Is Genprex, Inc. (GNPX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 36.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 36.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 38.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 36.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 38.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -1401.4% | |
| Return on Assets (ROA) | -273.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$17M |
| Free Cash Flow | -$17M |
| Current Ratio | 0.7 |
| Total Assets | $4M |
Price & Trading
| Last Close | $1.88 |
| 50-Day MA | $2.18 |
| 200-Day MA | $7.22 |
| Avg Volume | 1.1M |
| Beta | -0.7 |
|
52-Week Range
$1.71
| |
About Genprex, Inc. (GNPX)
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Genprex, Inc. (GNPX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Genprex, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Genprex, Inc.'s debt ratio?
Genprex, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Genprex, Inc.'s key financial metrics?
Genprex, Inc. has a market capitalization of $4M. Return on equity stands at -1401.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.